Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Louis Bourgeois

Showing results (31-40 of 70) with videos related to

Pageof 7
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 10, 2019
Consensus Report on Shigella Controlled Human Infection Model: Immunological AssaysRobert W Kaminski, Marcela F Pasetti, Ana Older Aguilar, et al.
Plos One|November 5, 2019
Evaluation of the reactogenicity, adjuvanticity and antigenicity of LT(R192G) and LT(R192G/L211A) by intradermal immunization in miceMilton Maciel, Mark Smith, Steven T Poole, et al.
Vaccine|August 1, 2009
Vaccination of children in low-resource countries against Shigella is unlikely to present an undue risk of reactive arthritisJ S Hill Gaston, Robert D Inman, Edward T Ryan, et al.
Vaccine|May 13, 2008
Safety and immunogenicity of WRSd1, a live attenuated Shigella dysenteriae type 1 vaccine candidateRobin McKenzie, Malabi M Venkatesan, Marcia K Wolf, et al.
Vaccine|November 11, 2023
Vaccine value profile for enterotoxigenic Escherichia coli (ETEC)Ibrahim Khalil, John D Anderson, Karoun H Bagamian, et al.
Current Topics in Microbiology and Immunology|May 26, 2022
Shigella-Controlled Human Infection Models: Current and Future PerspectivesKristen A Clarkson, Chad K Porter, Kawsar R Talaat, et al.
Bulletin of the World Health Organization|January 2, 2024
Reassessing potential economic value and health impact of effective <i>Shigella</i> vaccinesWilliam P Hausdorff, John D Anderson, A Louis Bourgeois, et al.
Vaccine|February 25, 2019
Live attenuated enterotoxigenic Escherichia coli (ETEC) vaccine with dmLT adjuvant protects human volunteers against virulent experimental ETEC challengeClayton Harro, A Louis Bourgeois, David Sack, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 10, 2019
Consensus Report on Shigella Controlled Human Infection Model: Conduct of StudiesKawsar R Talaat, A Louis Bourgeois, Robert W Frenck, et al.
Journal of Clinical Microbiology|March 23, 2010
Noroviruses as a cause of diarrhea in travelers to Guatemala, India, and MexicoHoonmo L Koo, Nadim J Ajami, Zhi-Dong Jiang, et al.
Pageof 7

Showing results (31-40 of 70) with videos related to

Sort By:
Pageof 7
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 10, 2019
Consensus Report on Shigella Controlled Human Infection Model: Immunological AssaysRobert W Kaminski, Marcela F Pasetti, Ana Older Aguilar, et al.
Plos One|November 5, 2019
Evaluation of the reactogenicity, adjuvanticity and antigenicity of LT(R192G) and LT(R192G/L211A) by intradermal immunization in miceMilton Maciel, Mark Smith, Steven T Poole, et al.
Vaccine|August 1, 2009
Vaccination of children in low-resource countries against Shigella is unlikely to present an undue risk of reactive arthritisJ S Hill Gaston, Robert D Inman, Edward T Ryan, et al.
Vaccine|May 13, 2008
Safety and immunogenicity of WRSd1, a live attenuated Shigella dysenteriae type 1 vaccine candidateRobin McKenzie, Malabi M Venkatesan, Marcia K Wolf, et al.
Vaccine|November 11, 2023
Vaccine value profile for enterotoxigenic Escherichia coli (ETEC)Ibrahim Khalil, John D Anderson, Karoun H Bagamian, et al.
Current Topics in Microbiology and Immunology|May 26, 2022
Shigella-Controlled Human Infection Models: Current and Future PerspectivesKristen A Clarkson, Chad K Porter, Kawsar R Talaat, et al.
Bulletin of the World Health Organization|January 2, 2024
Reassessing potential economic value and health impact of effective <i>Shigella</i> vaccinesWilliam P Hausdorff, John D Anderson, A Louis Bourgeois, et al.
Vaccine|February 25, 2019
Live attenuated enterotoxigenic Escherichia coli (ETEC) vaccine with dmLT adjuvant protects human volunteers against virulent experimental ETEC challengeClayton Harro, A Louis Bourgeois, David Sack, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 10, 2019
Consensus Report on Shigella Controlled Human Infection Model: Conduct of StudiesKawsar R Talaat, A Louis Bourgeois, Robert W Frenck, et al.
Journal of Clinical Microbiology|March 23, 2010
Noroviruses as a cause of diarrhea in travelers to Guatemala, India, and MexicoHoonmo L Koo, Nadim J Ajami, Zhi-Dong Jiang, et al.
Pageof 7